This review highlights the role of proteomics in identifying key biomarkers for idiopathic pulmonary fibrosis, indicating their clinical relevance for diagnosis and prognosis.
Key Points
Proteomics identifies biomarkers that could improve diagnosis and treatment options for pulmonary fibrosis.
Significant progress in understanding idiopathic pulmonary fibrosis could enhance therapy responses and management.
Recent advancements in mass spectrometry have expanded proteomic applications in identifying disease-relevant biomarkers.
The exploration of molecular pathways involved in pulmonary fibrosis offers insights into its pathogenesis and therapeutic targets.